Evidence map›Paper›PMID 32722701›Full record

ArticlePloS one2020

The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.

Adam Palayew, Samya R Stumo, Graham S Cooke, Sharon J Hutchinson, Marie Jauffret-Roustide, Mojca Maticic, Magdalena Harris, Ammal M Metwally, Homie Razavi, Jeffrey V Lazarus and 1 more

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Cost-Effectiveness of Hepatitis C Virus Case Finding and Treatment in Eastern Europe and Central Asia.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Adam PalayewMcGill University Department of Epidemiology, Biostatistics, and Occupational Health, Montreal, Quebec, Canada.
Samya R StumoBarcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
Graham S CookeDivision of Infectious Diseases, Imperial College, London, United Kingdom.
Sharon J HutchinsonSchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, United Kingdom.
Marie Jauffret-RoustideCermes3 (Inserm U988/CNRS UMR 8211/Ecole des Hautes Etudes en Sciences Sociales/Paris Descartes University), Paris, France.
Mojca MaticicClinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Magdalena HarrisDepartment of Public Health, Environments and Society, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Ammal M MetwallyCommunity Medicine Research Department, Medicine Research Division, National Research Centre, Giza, Egypt.ORCID 0000-0003-0575-5202
Homie RazaviCenter for Disease Analysis Foundation, Lafayette, CO, United States of America.
Jeffrey V LazarusBarcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.ORCID 0000-0001-9618-2299
Hep-CORE Study Group

Funding

Department of Health 14/02/17Department of Health RP-2016-07-012Medical Research Council MR/P025064/1
6 · The paper itself

Abstract

backgroundNew hepatitis C virus (HCV) treatments spurred the World Health Organization (WHO) in 2016 to adopt a strategy to eliminate HCV as a public health threat by 2030. To achieve this, key policies must be implemented. In the absence of monitoring mechanisms, this study aims to assess the extent of policy implementation from the perspective of liver patient groups.

methodsThirty liver patient organisations, each representing a country, were surveyed in October 2018 to assess implementation of HCV policies in practice. Respondents received two sets of questions based on: 1) WHO recommendations; and 2) validated data sources verifying an existing policy in their country. Academic experts selected key variables from each set for inclusion into policy scores. The similarity scores were calculated for each set with a multiple joint correspondence analysis. Proxy reference countries were included as the baseline to contextualize results. We extracted scores for each country and standardized them from 0 to 10 (best).

resultsTwenty-five countries responded. For the score based on WHO recommendations, Bulgaria had the lowest score whereas five countries (Cyprus, Netherlands, Portugal, Slovenia, and Sweden) had the highest scores. For the verified policy score, a two-dimensional solution was identified; first dimension scores pertained to whether verified policies were in place and second dimension scores pertained to the proportion of verified policies in-place that were implemented. Spain, UK, and Sweden had high scores for both dimensions.

conclusionsPatient groups reported that the European region is not on track to meet WHO 2030 HCV goals. More action should be taken to implement and monitor HCV policies.

Indexed as

Health PolicyPublic HealthData CollectionElectronic Health RecordsHealth Plan ImplementationHepacivirusHepatitis CHumansSurveys and QuestionnairesWorld Health Organization

Identifiers

PMID32722701
PMCPMC7386634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.